Latest Content

The frontline addition of cancer vaccine IO102-IO103 to pembrolizumab demonstrated an increase in PFS in patients with advanced melanoma.

Daniel Glidden, MS, PA-C, discusses key data oncology APPs should be aware of and how to start incorporating exercise in cancer care.

T-DXd plus pertuzumab improved PFS and DOR across HER2+ breast cancer subgroups, regardless of prior therapy or PIK3CA mutation status.

Disitamab vedotin/toripalimab improved PFS and OS vs chemotherapy in HER2-expressing advanced urothelial carcinoma, per phase 3 RC48-C016 data.

Treatment for patients with R/R multiple myeloma should be based on the individual patient and their history, said Lisa Hwa Christenson, DNP, APRN, CNP.

Among lymphoma survivors, a multidisciplinary intervention program had a beneficial effect on fatigue and aspects of health-related quality of life.

Twenty-year follow-up demonstrated continued imatinib efficacy in advanced GIST with doubled median overall survival.

Using gender-neutral language is the first step in making a safe space for LGBTQIA+ patients with cancer, explained Al Asante-Facey, PA, MBA.

Supervised physical activity, while feasible, was not shown to affect quality of life or fatigue in patients with metastatic cancer.

Korie Bigbee, DNP, explains the necessity of survivorship care and how to enact changes to make it more accessible to patients with cancer.

Dermatitis and lymphedema are among the most pertinent adverse effects of radiation to the breast, according to Alexa M. Lantz, MSPAS, PA-C.

La-Urshalar Brock, FNP-BC, CNM, describes tactics for managing dermatologic AEs in patients with breast cancer as part of a multidisciplinary care team.

Kevin Y. Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment planning in solid tumors.